Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – iClick Interactive Asia Group Limited (NASDAQ: ICLK) Announces Launch of One-Stop Solution – iNsights

iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced the launch of its flagship marketing analysis tool, iNsights, which gives brands in-depth and actionable consumer behavior insights to drive more effective marketing campaigns. According to the update, iNsights is an efficient one-stop solution that tracks and analyzes cross-channel campaigns covering China and overseas markets. “iNsights effectively addresses the difficulties presented to marketers by the shallow insights provided by raw data and selective sampling data analysis, as well as the inconvenience and incomparability of multiple tracking systems for different regions,” said Frankie Ho, president of International Business at iClick, in the news release. “Our recent update of iAudience and the launch of iActivate and iNsights are part of iClick’s commitment to continually build up and develop the best full-stack solutions for global marketers. iClick has always devoted itself to helping brands gain a better and deeper understanding of markets in real time and to creating the best marketing strategies driven by data and advanced algorithms.”

To view the full press release, visit https://ibn.fm/MivoT

About iClick Interactive Asia Group Limited

iClick Interactive Asia Group is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide, including Asia and Europe.

For more information, please visit ir.i-Click.com.

NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in iClick Interactive Asia Group Ltd. ICLK, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) Featured in Exclusive Broadcast

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced that it was featured in a broadcast titled, “New Opportunities Abound for Specialty Beverage, Water Companies.” The piece highlights significant M&A potential for smaller specialty brands and reads, “Companies such as The Alkaline Water Company, one of the fastest-growing enhanced water companies in the industry, could be an attractive option. . . . Alkaline88 remains one of the top-selling brands in the value-added water category. According to recent trade data, Alkaline88 reported double-digit growth despite the value added water category contracting 8.2% for the four-week period ending April 18, 2020.”

To hear the AudioPressRelease and view the full editorial, visit https://ibn.fm/OVVJN and https://ibn.fm/QtF5j 

To view the full press release, visit https://ibn.fm/uqf1x

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER   

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, The Alkaline Water Company Inc. WTER | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials

180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, designed to block the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases. The company is advancing on this front as discussed by a recent article that reads, “180 Life Sciences’ lead program is in phase 2b/3 clinical trials and expects to deliver its first results next year. Other clinical trials planned by the company are scheduled to begin later this year, and two additional programs are in the preclinical stage.”

To view the full article, visit https://ibn.fm/VxHdq

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. KBL Merger Corp. IV (NASDAQ: KBLM) previously announced plans to merge with 180 Life Sciences and, in connection with the merger, consummated a bridge financing on June 29, 2020, and submitted its latest S4 filing with the SEC on August 28, 2020. Close of the business combination is expected in the fourth quarter of 2020. Following the merger, the new company will be listed on the Nasdaq Capital Market under ticker symbol “ATNF.” For more information, visit the company’s website at www.180LifeSciences.com.

KBLM has valued 180 Life Sciences at $175 million, with the acquisition being carried out via a share swap, with each share of 180 Life Sciences to be exchanged for one share of KBLM.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

MissionIRNewsBreaks – SRAX Inc.’s (NASDAQ: SRAX) Sequire Provides Key Insight for Public Company Execs

SRAX (NASDAQ: SRAX), a provider of digital-marketing and consumer data-management technology products, gives public companies an edge with critical data to successfully activate media campaigns, engage shareholders and attract investment. The company’s data analytics platform – Sequire – has proven a key tool for decision makers in the public realm, recently doubling its user base to amass over 1 million active investors and traders. A recent article discussing this quotes SRAX founder and CEO Christopher Miglino, who states, “We are creating a community of public company executives that are taking back their data. For too long these leaders have relied on subpar data to make important capital market decisions. Our clients have seen notable results from Sequire and our marketing services, and the more companies that join in our mission, the better the platform gets at identifying and securing investors. The retail investor is becoming a bigger part of the cap table and we have mastered the connection between trading platforms such as Robinhood and the public issuer, just as these platforms attempt to become less transparent.

To view the full article, visit https://ibn.fm/jcftZ

About SRAX                                                                               

SRAX is a digital-marketing and consumer data-management technology company. SRAX’s technology unlocks data for brands in the CPG, investor relations, luxury and lifestyle verticals. Through its various platforms, SRAX is monetizing its data sets and growing multiple recurring revenue streams. BIGtoken is a consumer-managed data marketplace where people can own and earn from their data. The platform also provides advertisers and media companies access to transparent, verified consumer data to better reach and serve audiences. Sequire is a premier platform for investor intelligence and communication. Through Sequire, public companies can track their investors’ behaviors and trends, and use those insights to engage current and potential investors across marketing channels. For more information on SRAX and its verticals, visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in SRAX, Inc. SRAX | Leave a comment

MissionIRNewsBreaks – Cybin Corp. Leverages Two-Pronged Approach to Target Psychedelic, Nutraceutical Sectors

Cybin Corp., a Canada-based life-science company, looks to benefit from its growing footprint in two billion-dollar markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see significant growth in the coming years. The global nutraceutical market was valued at $382.51 billion in 2019 and is expected to grow at an 8.3% compound annual growth rate (“CAGR”) over the next seven years. Meanwhile, the psychedelic drugs market is projected to reach $6.85 billion by 2027. Cybin’s business model is structured around two wholly owned divisions focused on targeting both promising spaces. A recent article discussing this reads, “Cybin is committed to advancing research and development (‘R&D’) through its intellectual property portfolio in the psychedelic and nutraceutical spaces. Based on the company’s unique psilocybin extraction methods, delivery mechanisms and new formulations, a variety of indications for mental health will be addressed.”

To view the full article, visit https://ibn.fm/CcdHa

About Cybin Corp.

Cybin is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Cybin Corp. | Leave a comment

MissionIRNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) Shines Spotlight on Dynamic Platform Capabilities

Trxade Group (NASDAQ: MEDS), an integrated drug-procurement, delivery and health-care platform, recently had the opportunity to showcase its growing medical technology accomplishments at multiple virtual investor conferences. Trxade Group CEO Suren Ajjarapu took the company’s message well beyond physical borders to virtual summits in the month of September, providing insight into the dynamic capabilities and expansion of the Trxade Exchange platform. A recent article discussing this reads, “Trxade Group has been building its B2B platform into a B2C-friendly portfolio that helps independent local pharmacies compete with large-scale retail chains through drug pricing transparency and network strength. The platform also assists health patients to gain telemedicine access to physicians’ clinics without leaving home, and to have prescriptions ordered online and delivered to the home (https://ibn.fm/zcxwL).

To view the full article, visit https://ibn.fm/ccEDS

About Trxade Group Inc.

Headquartered in Tampa, Florida, Trxade Group is an integrated drug-procurement, delivery and health-care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health-care services affordable and accessible. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms: (1) the Trxade B2B trading platform with 11,725 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; (3) the Bonum Health platform offering affordable telehealth services; and (4) the DelivMeds app, which coordinates a nationwide distribution network through independent pharmacies or mail-order delivery. For additional information, please visit www.Trxade.com, www.DelivMeds.com and www.BonumHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Trxade Group Inc. (MEDS) | Leave a comment

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

  • CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer.
  • In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit.
  • In preclinical studies, the company’s second drug candidate, a novel DNA binding agent, was 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation.
  • A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade.
  • Industry reports estimate that the global brain tumor therapeutics market will reach $2.74 billion in 2023 and $3.4 billion by 2025, up from $2.25 billion in 2019.

CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (“API”) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://ibn.fm/QOqjB).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021

  • Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027
  • Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade
  • The number of conditions with chronic inflammation is expected to increase persistently over the next 30 years in the United States.
  • 180 Life Sciences is in the process of being acquired by KBLM Merger Corp. and the acquisition is expected to finalize in Q4 2020

Clinical-stage biotechnology company 180 Life Sciences Corp. is leading the way with research into the world’s most significant driver of disease – inflammation. Part of the body’s natural defense system by removing foreign stimuli from the body to begin the healing process, inflammation plays a significant role in a wide range of diseases and ailments, including asthma, arthritis, psoriasis, COVID-19 and more.

Inflammation within the body presents itself in two forms – acute and chronic. The World Health Organization (“WHO”) ranks chronic diseases (like a chronic inflammatory disease) as the most significant risk to human health. The conditions associated with chronic inflammation are anticipated to increase persistently over the next 30 years within the United States.

In 2014, the Rand Corporation estimated that 60% of Americans had at least one chronic condition, 42% had more than one, and 12% of adults had five or more chronic conditions. In 2000, 125 million Americans lived with chronic diseases, and 61 million had more than one (https://ibn.fm/jE8Tw).

180 Life Sciences is devoting its clinical-stage biotechnology research to producing solutions that will help health professionals battle inflammation. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, which seeks to suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases.

The company’s fibrosis and anti-TNF clinical trials (phase 2b/3) are conducted at the Kennedy Institute within Oxford University and led by Professor Jagdeep Nanchahal and Professor Sir Marc Feldmann. The first results of these trials, addressing four critical areas of inflammation – Dupuytren’s disease, frozen shoulder, post-operative cognitive deficit, and liver fibrosis and nonalcoholic steatohepatitis – are expected in 2021.

180 Life Sciences is also running two preclinical stage trials regarding chronic inflammatory pain (at the Hebrew University in Israel and led by Professor Raphael Mechoulam) and the a7nAChR nicotine receptor and its role in the body’s method of controlling inflammation (at Stanford University and led by Professor Lawrence Steinman and Dr. Jonathan Rothbard).

The company’s work addressing inflammation makes it an attractive investment, as its potential for growth is significant given the size and expansion rate of the anti-inflammatory therapeutics market. According to Allied Market Research, the anti-inflammatory drug therapy market is expected to grow to approximately $106.1 billion annually in 2020 (https://ibn.fm/iC9AZ). From 2015 to 2020, the registered CAGR would be 5.9%. According to Fortune Business Insights, the market is expected to continue growing and generating revenue of $191.42 billion through 2027 (https://ibn.fm/d9Zp4).  

In addition, Professor Sir Marc Feldmann, who leads the Fibrosis & Anti-TNF trial, has already developed and marketed an anti-TNF drug (Remicade). He developed this very first anti TNF inhibitor with Dr. James Woody, who was Chief Scientific Officer at Centocor, and will serve as CEO of 180LS. Remicade was the primary driver in the $4.9 billion acquisition of Centocor by Johnson & Johnson in 1998.  Remicade was developed with the Today, Remicade remains one of the bestselling anti-TNF drugs for Johnson & Johnson. The global sales for anti-TNFs in 2016 were $36 billion.

180 Life Sciences Corp. is currently nearing the end of a merger with special purpose acquisition company KBL Merger Corp. IV (NASDAQ: KBLM), which should finalize in Q4 2020. Once the merger has been completed, 180 Life Sciences will be listed on the NASDAQ Capital Market under the ticker symbol ‘ATNF.’ At present, KBL Merger Corp. IV values 180 Life Sciences Corp. at an estimated $175 million, with the acquisition being carried out through share swapping.

For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

MissionIRNewsBreaks – Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) Announces AGM Results

Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, on Thursday announced voting results of its annual general and special meeting of shareholders (“AGM”). According to the update, shareholders voted in favor of each of the presented items of business, including the election of the director nominees listed in the company’s management information circular. This included the election of Garth Hankinson, who currently serves as executive VP and CFO of Constellation Brands Inc., to the Canopy Rivers Board of Directors. John Bell, the board’s former chair, did not seek re-election at the meeting. “We thank John for his commitment and dedication to Canopy Rivers. His experience and guidance have been invaluable as we navigated the early days of the cannabis sector,” said Narbe Alexandrian, president and CEO of Canopy Rivers, in the news release. “We are also excited to welcome Garth to our board. We believe that his expertise in finance and M&A will benefit both Canopy Rivers and our portfolio.”

To view the full press release, visit https://ibn.fm/nj8yv

About Canopy Rivers Inc.

Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 18 companies across various segments of the cannabis value chain. Canopy Rivers believes that bringing together people, capital and ideas raises the potential of the entire cannabis industry. By leveraging its industry insights, in-house expertise, and thesis-driven approach to investing, Canopy Rivers aims to provide shareholders with exposure to specialized and disruptive cannabis companies. The company’s mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with its portfolio, Canopy Rivers is helping build the cannabis industry of tomorrow, today. For more information, visit www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://ibn.fm/CNPOF   

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Canopy Rivers Inc. CNPOF, Canopy Rivers Inc. RIV, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) Expanding A88CBD(TM) Line with Highly Anticipated Ingestible and Topical Products

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, on Thursday announced that it will introduce new A88CBD(TM) infused ingestible and topical products for its lifestyle brand at A88CBD.com and select retail outlets. According to the update, the new products will be available in October 2020. “We are excited to announce our much-awaited A88CBD line of gummies available in four exciting flavors. Also, we strengthened our water portfolio with a new Lemon-Lime CBD flavored water and our A88CBD topicals portfolio with a deep-relief cream and bath bombs,” said WTER president and CEO Ricky Wright in the press release. “As a trusted lifestyle brand, our new products are all-natural and zero-calorie and include the same high-quality and lab-tested CBD. Guided by data-driven insights and carefully curated formulations, we believe these new items for our A88CBD line are some of the best in the industry. The all-natural element of our ingestible and topical line fits well with our target demographic of consumers seeking healthier alternatives. We are well-positioned with our channel partners, which serve this demographic, and our sales pipeline continues to build across traditional brick-and-mortar retailers, MSOs, dispensaries, and online wholesalers. We already have commitments from over 100 recently announced retail stores to carry our exciting new products, which will also be available online on our e-commerce site, A88CBD.com, and online-only stores. We anticipate our A88CBD line to be a solid contributor to our top-line during the second half of our current fiscal year and beyond.”

To view the full press release, visit https://ibn.fm/nGesj

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER   

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, The Alkaline Water Company Inc. WTER | Leave a comment